In a reproductive‑age woman taking Slynd (drospirenone‑only oral contraceptive) for dysmenorrhea who developed facial, chest, and back acne after 5–6 months, does the medication improve acne?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Slynd (Drospirenone-Only) Will NOT Improve Acne and May Be Worsening It

You should discontinue Slynd and switch to a combined oral contraceptive (COC) containing both estrogen and progestin, as progestin-only pills like Slynd may worsen acne. 1

Why Slynd Is Likely Causing the Acne

The 2024 AAD guidelines explicitly state that "progestin-only oral contraceptive pills, intramuscular injections, intrauterine devices, or subcutaneous implants may worsen acne." 1 This is the critical evidence here. While drospirenone has antiandrogenic properties when combined with estrogen, when used alone as a progestin-only pill, it lacks the estrogen component necessary to provide net antiandrogenic effects that treat acne.

The mechanism is straightforward:

  • Combined oral contraceptives (COCs) treat acne through overall anti-androgenic properties: they decrease ovarian androgen production, increase sex hormone-binding globulin, and reduce free testosterone
  • Progestins alone (even fourth-generation ones like drospirenone) do not provide these benefits without estrogen 1
  • The timing of your patient's acne development (5-6 months after starting Slynd) is consistent with a medication-induced effect

What You Should Do Instead

Switch to a combined oral contraceptive (COC) containing ethinyl estradiol plus drospirenone if there are no contraindications to estrogen. The AAD conditionally recommends COCs for acne treatment based on moderate certainty evidence, with four FDA-approved formulations including drospirenone/ethinyl estradiol combinations. 1

Algorithm for Decision-Making:

  1. Screen for COC contraindications:

    • Age >35 years AND tobacco use
    • History of VTE, stroke, or MI
    • Hypertension or diabetes with vascular complications
    • Migraine with aura
    • Obtain blood pressure measurement
  2. If no contraindications exist: Switch to drospirenone/ethinyl estradiol COC

    • This maintains the dysmenorrhea benefit while treating acne
    • Expect acne improvement by cycle 6 based on RCT data 1
  3. If estrogen is contraindicated: Consider alternative acne treatments (topical retinoids, benzoyl peroxide, or oral antibiotics) while continuing Slynd for dysmenorrhea, OR switch to a different dysmenorrhea treatment

Supporting Evidence from Recent Research

A 2025 study showed that drospirenone-only therapy (4 mg) significantly reduced acne in PCOS patients after 6 months (CASS scores decreased from 2.4 to 1.8, p=0.02) 2. However, this contradicts the guideline statement and may reflect the specific hyperandrogenic pathophysiology of PCOS rather than general acne treatment. In your patient without PCOS who developed acne AFTER starting Slynd, the guideline warning about progestin-only pills worsening acne takes precedence.

Critical Pitfall to Avoid

Do not assume that because drospirenone is a "fourth-generation" progestin with antiandrogenic properties, it will improve acne when used alone. The antiandrogenic benefit requires combination with estrogen to achieve net hormonal effects that treat acne. 1

References

Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.